Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab

Authors :: Deepti Aurora-Garg
F. Jin
Eric H. Rubin
Jared Lunceford
J Hopkins
David Fabrizio
A. Snyder
Priti Hegde
Lee A. Albacker
Razvan Cristescu
A. Ward
Source :: Annals of Oncology. 32:1193-1194
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
business.industry
MEDLINE
Cancer
Hematology
Pembrolizumab
Antibodies, Monoclonal, Humanized
medicine.disease
Text mining
Neoplasms
Internal medicine
Prevalence
medicine
Humans
business

Tools